BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 11241900)

  • 1. Detection of malignant effusions: comparison of a telomerase assay and cytologic examination.
    Braunschweig R; Yan P; Guilleret I; Delacretaz F; Bosman FT; Mihaescu A; Benhattar J
    Diagn Cytopathol; 2001 Mar; 24(3):174-80. PubMed ID: 11241900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pitfalls in TRAP assay in routine detection of malignancy in effusions.
    Braunschweig R; Guilleret I; Delacrétaz F; Bosman FT; Mihaescu A; Benhattar J
    Diagn Cytopathol; 2001 Oct; 25(4):225-30. PubMed ID: 11599105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telomerase activity in effusions: a comparison between telomere repeat amplification protocol in situ and conventional telomere repeat amplification protocol assay.
    Hansson M; Zendehrokh N; Ohyashiki J; Ohyashiki K; Westman UB; Roos G; Dejmek A
    Arch Pathol Lab Med; 2008 Dec; 132(12):1896-902. PubMed ID: 19061286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of the human telomerase RNA component by in situ hybridization in cells from body fluids.
    Nieh S; Chen SF; Fu E; Jan CI; Lee WH
    Acta Cytol; 2005; 49(1):31-7. PubMed ID: 15717752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytological diagnosis and telomerase activity of cells in effusions of body cavities.
    Toshima S; Arai T; Yasuda Y; Takaya T; Ito Y; Hayakawa K; Shibuya C; Yoshimi N; Shibayama M; Kashiki Y
    Oncol Rep; 1999; 6(1):199-203. PubMed ID: 9864428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Telomere repeat amplification protocol (TRAP) in situ reveals telomerase activity in three cell types in effusions: malignant cells, proliferative mesothelial cells, and lymphocytes.
    Zendehrokh N; Dejmek A
    Mod Pathol; 2005 Feb; 18(2):189-96. PubMed ID: 15389260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Limitations of detection of malignancy in pleural effusions using ELISA-based TRAP assay: comparison with cytological examination.
    Lee WY
    Cytopathology; 2005 Oct; 16(5):227-32. PubMed ID: 16181308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene expression analysis of the catalytic subunit of human telomerase (hEST2) in the differential diagnosis of serous effusions.
    Nagel H; Schlott T; Schulz GM; Droese M
    Diagn Mol Pathol; 2001 Mar; 10(1):60-5. PubMed ID: 11277397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telomerase activity in pleural effusions: diagnostic significance.
    Yang CT; Lee MH; Lan RS; Chen JK
    J Clin Oncol; 1998 Feb; 16(2):567-73. PubMed ID: 9469342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Telomerase activity analyzed with TRAP in situ provides additional information in effusions remaining equivocal after immunocytochemistry and hyaluronan analysis.
    Adell E; Dejmek A
    Diagn Cytopathol; 2014 Dec; 42(12):1051-7. PubMed ID: 24692425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telomerase enzyme activity as a diagnostic tool to distinguish effusions of malignant and benign origin.
    Spangler EA; Rogers KS; Thomas JS; Pustejovsky D; Boyd SL; Shippen DE
    J Vet Intern Med; 2000; 14(2):146-50. PubMed ID: 10772485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expressions of human telomerase mRNA component (hTERC) and telomerase reverse transcriptase (hTERT) mRNA in effusion cytology.
    Hiroi S; Nakanishi K; Kawai T
    Diagn Cytopathol; 2003 Oct; 29(4):212-6. PubMed ID: 14506674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytohistological correlation in serous effusions using the newly proposed International System for Reporting Serous Fluid Cytopathology: Experience of an oncological center.
    Lobo C; Costa J; Petronilho S; Monteiro P; Leça L; Schmitt F
    Diagn Cytopathol; 2021 May; 49(5):596-605. PubMed ID: 32339444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of hyperdiploid malignant cells in body cavity effusions by fluoresence in situ hybridization on ThinPrep slides.
    Florentine BD; Sanchez B; Raza A; Frankel K; Martin SE; Kovacs B; Felix JC
    Cancer; 1997 Oct; 81(5):299-308. PubMed ID: 9349518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosis and categorization of malignant effusions: A 6-year review from a single academic institution.
    Lew M; Cantley R; Heider A; Jing X
    Diagn Cytopathol; 2021 May; 49(5):615-621. PubMed ID: 32275354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of telomerase activity between malignant and tuberculous pleural effusions.
    Maneechotesuwan K; Lertworawiwat A; Tscheikuna J; Wamanuttajinda V
    J Med Assoc Thai; 2006 Nov; 89 Suppl 5():S46-54. PubMed ID: 17718245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telomerase activity in body cavity fluid and peritoneal washings in uterine and ovarian cancer.
    Murakami J; Nagai N; Ohama K
    J Int Med Res; 1998; 26(3):129-39. PubMed ID: 9718467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early diagnosis of mesothelioma in serous effusions using AgNOR analysis.
    Pomjanski N; Motherby H; Buckstegge B; Knops K; Rohn BL; Böcking A
    Anal Quant Cytol Histol; 2001 Apr; 23(2):151-60. PubMed ID: 11332082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphoreticular malignancies in serous effusions: Cytomorphologic, flow cytometric and immunocytochemical analysis.
    Gupta P; Pandey T; Gautam U; Rajwanshi A; Srinivasan R; Gupta N; Rohilla M; Varma N; Dey P
    Diagn Cytopathol; 2021 May; 49(5):647-656. PubMed ID: 33629825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telomerase activity in benign and malignant cytologic fluids.
    Mu XC; Brien TP; Ross JS; Lowry CV; McKenna BJ
    Cancer; 1999 Apr; 87(2):93-9. PubMed ID: 10227600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.